The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Improving treatment approaches for unfit patients with FLT3-mutated AML
In this video, Juan Miguel Bergua-Burgues, MD, Hospital San Pedro de Alcantara, Cáceres, Spain, comments on the need to identify optimal treatment options for unfit patients with FLT3-mutated acute myeloid leukemia (AML), highlighting the lack of an approved FLT3 inhibitor in this patient population. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There is a gap in the treatment of this type of patient with FLT3 because we have not approved any inhibitors of FLT3 in patients with this type of acute myeloid leukemia. Midostaurin is only approved with intensive chemotherapy, and Gilteritinib and Quizartinib are not approved in combination with aza-ven. We need a FLT3 inhibitor in this type of patient. And surely, I confess that perhaps even in patients with FLT3 negative, as the QUIWI trial shows, we can benefit the patients with acute myeloid leukemia de novo...
There is a gap in the treatment of this type of patient with FLT3 because we have not approved any inhibitors of FLT3 in patients with this type of acute myeloid leukemia. Midostaurin is only approved with intensive chemotherapy, and Gilteritinib and Quizartinib are not approved in combination with aza-ven. We need a FLT3 inhibitor in this type of patient. And surely, I confess that perhaps even in patients with FLT3 negative, as the QUIWI trial shows, we can benefit the patients with acute myeloid leukemia de novo. But we have to prove this assessment that I make. We have to make. But it’s very important to include FLT3 inhibitors associated with aza-ven, decreasing the toxicity, decreasing the days of Venetoclax, decreasing the dose of Azacitidine or the dose of Cytarabine, and see which is the best combination of an inhibitor and the current standard of treatment in older patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
